Quick Answer
Scinai Immunotherapeutics Ltd. reported Operating Income Loss of -$8.64 million for the year ending 2024.
- Scinai Immunotherapeutics Ltd. showed an increase of +11.0% in Operating Income Loss from 2023 to 2024.
- This data is from Scinai Immunotherapeutics Ltd.'s annual report (Form 10-K), filed with the SEC on May 7, 2025.
- XBRL data for this metric is available from 2021 to 2024 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 4 years of available data (2021 to 2024), Scinai Immunotherapeutics Ltd.'s Operating Income Loss has grown by 20.5%.
- Historical annual values: Fiscal year 2024: -$8.64 million | Fiscal year 2023: -$9.71 million | Fiscal year 2022: -$11.06 million | Fiscal year 2021: -$10.86 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: